Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12051156 | 0.93 | SCN9A (0.51) | SCN9ASCN5ABRD4CREBBPCNR2 | |
| SCHEMBL15177794 | 0.86 | SCN9A (0.48) | SCN9ASCN5ADRD2SLC6A4APP | |
| SCHEMBL899454 | 0.83 | SCN9A (0.64) | SCN9ASCN5ABRD4CREBBPCNR2 | |
| SCHEMBL1260945 | 0.82 | SCN9A (0.65) | SCN9ASCN5ABRD4CREBBPCNR2 | |
| SCHEMBL28472685 | 0.80 | APP (0.55) | SCN9ASCN5ABRD4CREBBPCNR2 | |
| SCHEMBL12051155 | 0.80 | SCN9A (0.53) | SCN9ASCN5ABRD4CREBBPCNR2 | |
| SCHEMBL12051160 | 0.79 | SCN9A (0.47) | SCN9ASCN5ABRD4CREBBPCNR2 | |
| SCHEMBL12927838 | 0.79 | DRD2 (0.43) | SCN9ASCN5ADRD2SLC6A4APP | |
| SCHEMBL14615090 | 0.79 | SCN9A (0.52) | SCN9ASCN5ABRD4CREBBPCNR2 | |
| SCHEMBL12190627 | 0.78 | SCN9A (0.48) | SCN9ASCN5ABRD4CREBBPCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103333162-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT | 2013-10-02 | — | — | CN | disclosed |
| CN-103319464-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT | 2013-09-25 | — | — | CN | disclosed |
| CN-103304541-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT | 2013-09-18 | — | — | CN | disclosed |
| EP-2626354-A1 | Viral polymerase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1718608-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| CN-102911161-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT | 2013-02-06 | — | — | CN | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| CN-1984908-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-06-20 | — | — | CN | disclosed |
| EP-1771442-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-11 | — | — | EP | disclosed |
| CN-1922174-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-02-28 | — | — | CN | disclosed |
| EP-1718608-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20060052418-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| WO-2006007693-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
| US-20050222236-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080388-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222236-A1 | Viral polymerase inhibitors | POLR2A, POLR1E, RPP30 | SCN9A 390/4885SCN5A 1444/4885BRD4 603/4885 |
| US-20060052418-A1 | Viral polymerase inhibitors | RPP30, POLR2A, POLR1E | SCN9A 333/4885SCN5A 1345/4885BRD4 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.